Multiple Rising Dose Study of MK-6194 in Participants With Atopic Dermatitis (MK-6194-008)
Public ClinicalTrials.gov record NCT05450198. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Dose Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-6194 in Participants With Moderate to Severe Atopic Dermatitis
Study identification
- NCT ID
- NCT05450198
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Enrollment
- 72 participants
Conditions and interventions
Conditions
Interventions
- MK-6194 Biological
- Placebo Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 7, 2022
- Primary completion
- May 21, 2024
- Completion
- May 21, 2024
- Last update posted
- Jun 4, 2025
2022 – 2024
United States locations
- U.S. sites
- 13
- U.S. states
- 8
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arkansas Research Trials-Clinical Trials ( Site 0002) | North Little Rock | Arkansas | 72117 | — |
| Miami Dermatology and Laser Research ( Site 0025) | Miami | Florida | 33173 | — |
| Global Health Research Center, Inc. ( Site 0005) | Miami Lakes | Florida | 33016 | — |
| Genesis Clinical Research, LLC ( Site 0004) | Tampa | Florida | 33603 | — |
| ForCare Clinical Research ( Site 0003) | Tampa | Florida | 33613 | — |
| Advanced Medical Research, PC. ( Site 0027) | Sandy Springs | Georgia | 30328 | — |
| AXIS Clinicals ( Site 0029) | Dilworth | Minnesota | 56529 | — |
| Remington Davis Clinical Research ( Site 0021) | Columbus | Ohio | 43215 | — |
| Paddington Testing Company ( Site 0010) | Philadelphia | Pennsylvania | 19103 | — |
| North Texas Center for Clinical Research ( Site 0028) | Frisco | Texas | 75034 | — |
| Progressive Clinical Research ( Site 0022) | San Antonio | Texas | 78213 | — |
| Complete Dermatology ( Site 0023) | Sugar Land | Texas | 77478 | — |
| Premier Clinical Research ( Site 0026) | Spokane | Washington | 99202 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05450198, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 4, 2025 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05450198 live on ClinicalTrials.gov.